Related references
Note: Only part of the references are listed.Immunological dynamics after subcutaneous immunization with a squalene-based oil-in-water adjuvant
Sjoerd T. T. Schetters et al.
FASEB JOURNAL (2020)
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Laura Evgin et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice
Amelia S. Aitken et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Nikolas Tim Martin et al.
MOLECULAR THERAPY (2018)
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Shashi Gujar et al.
TRENDS IN IMMUNOLOGY (2018)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
Personalized cancer vaccines: Targeting the cancer mutanome
Xiuli Zhang et al.
VACCINE (2017)
Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation
Ruta Veinalde et al.
ONCOIMMUNOLOGY (2017)
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies
Amelia Sadie Aitken et al.
BIOMEDICINES (2017)
Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination
Byram W. Bridle et al.
JOURNAL OF IMMUNOLOGY (2016)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Immunogenicity of somatic mutations in human gastrointestinal cancers
Eric Tran et al.
SCIENCE (2015)
Maraba Virus as a Potent Oncolytic Vaccine Vector
Jonathan G. Pol et al.
MOLECULAR THERAPY (2014)
Alum and Squalene-Oil-in-Water Emulsion Enhance the Titer and Avidity of Anti-Aβ Antibodies Induced by Multimeric Protein Antigen (1-11)E2, Preserving the Igg1-Skewed Isotype Distribution
Francesca Mantile et al.
PLOS ONE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Mutated tumor alleles are expressed according to their DNA frequency
John C. Castle et al.
SCIENTIFIC REPORTS (2014)
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines
Byram W. Bridle et al.
ONCOIMMUNOLOGY (2013)
Exploiting the Mutanome for Tumor Vaccination
John C. Castle et al.
CANCER RESEARCH (2012)
Adoptive Transfer of Cytotoxic T Lymphocytes Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape
Karen M. Kaluza et al.
HUMAN GENE THERAPY (2012)
Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine
Chantal G. Lemay et al.
MOLECULAR THERAPY (2012)
Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus
Jan Brun et al.
MOLECULAR THERAPY (2010)
Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
Fabrice Le Boeuf et al.
MOLECULAR THERAPY (2010)
Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With Adenovirus
Byram W. Bridle et al.
MOLECULAR THERAPY (2009)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
DF Stojdl et al.
CANCER CELL (2003)
Share Paper
